TRMU-Related Acute Infantile Liver Failure (TRMU Deficiency): Comprehensive Research Report

1. Disease Information

Overview

TRMU-related acute infantile liver failure — clinically termed TRMU deficiency — is an autosomal recessive mitochondrial disorder caused by biallelic pathogenic variants in TRMU (tRNA 5-methylaminomethyl-2-thiouridylate methyltransferase, also called MTU1). It is characterized by transient, life-threatening acute liver failure presenting in infancy (classically ages 2–4 months), accompanied by severe lactic acidosis, hypoglycemia, hyperammonemia, and poor weight gain. A defining and clinically critical feature is that, unlike most mitochondrial hepatopathies, survivors of the acute episode typically show full clinical and biochemical resolution of liver disease with no recurrence — hence "transient" (GeneReviews, NBK591557, updated May 2023; OMIM #613070).

Key Identifiers

Synonyms

Reversible infantile liver failure (RILF); transient infantile liver failure due to TRMU mutations; mitochondrial DNA depletion-like syndrome due to TRMU deficiency; MTU1 deficiency.

Evidence base

Information is derived from aggregated disease-level resources (OMIM, Orphanet, GeneReviews, MalaCards) built from pooled case series and cohort studies (not raw EHR data) — most authoritatively the GeneReviews chapter (Vogel et al., 2023) and the largest published cohort to date, Murali et al. and colleagues' Genetics in Medicine study of 62 individuals from 56 families (Vogel CH et al., "Genotypic and phenotypic spectrum of infantile liver failure due to pathogenic TRMU variants," Genet Med 2022 Dec, PMID: 36305855).

2. Etiology

Disease Causal Factors

The sole known cause is biallelic (homozygous or compound heterozygous) pathogenic loss-of-function variants in TRMU (22q13.31), which abolish or reduce the enzyme's 2-thiolation activity on mitochondrial tRNAs. This is a purely genetic/mitochondrial-translation disease; there is no known infectious or purely environmental primary cause, though physiologic/metabolic stress is a key disease-triggering cofactor (see below).

Genetic Risk Factors

• Causal variants: missense, nonsense, frameshift, splice-site, and small indel variants throughout TRMU; sequence analysis detects ~93% (26/28) of pathogenic alleles, with gene-targeted deletion/duplication analysis detecting the remainder (~7%, 2/28) (GeneReviews).
• Founder variant: c.229T>C (p.Tyr77His) is a well-documented founder mutation in the Yemenite Jewish population, first described by Zeharia et al. (2009, Am J Hum Genet, PMID: 19732863), the paper that originally established TRMU as the causal gene for this syndrome.
• Loss-of-function (nonsense/frameshift/splice) variants are significantly associated with worse survival than missense/in-frame indel variants (10/20 deaths in LOF carriers vs. 10/42 in missense/in-frame carriers; p=0.022; GeneReviews, citing Vogel et al. 2023).
• c.2T>A (p.Met1?) (loss of the start codon) is specifically associated with early mortality despite aggressive management (observed in 5 deceased individuals).

Environmental / Physiologic Risk Factors

• Age window of vulnerability: acute liver failure occurs almost exclusively within the first year of life (43/62 individuals in the largest cohort), with a specific window of increased risk around 1–4 months of age.
• Intercurrent illness/physiologic stress: episodes are typically precipitated by febrile illness or other metabolic stress; patients are often well between episodes.
• Low endogenous cysteine: infants have a physiologic nadir in cystathionase (cystathionine γ-lyase) activity, making cysteine a conditionally essential amino acid in the neonatal/infantile period — this is the key gene-environment (developmental) interaction underlying disease timing (Murali et al., Mol Genet Metab 2021, PMID: 33485800).
• A case report documents cytomegalovirus infection aggravating/precipitating fatal hepatic dysfunction in a TRMU-mutation carrier (Cureus case report), illustrating infection as a secondary stressor rather than a primary cause.

Protective Factors

• Presymptomatic/prenatal cysteine + N-acetylcysteine (NAC) supplementation in at-risk siblings (identified via prior affected sibling) is associated with a milder clinical course, less severe acidosis/liver dysfunction, and fewer hospitalizations (GeneReviews).
• The p.Tyr77His founder allele itself appears relatively protective/lower-mortality compared with other genotypes (0/8 deaths in homozygotes; 1/9 in compound heterozygotes in the Vogel et al. cohort).

Gene-Environment Interaction

The central gene-environment interaction in this disease is the intersection of (1) genetically reduced TRMU thiolation capacity with (2) the developmentally programmed, transient physiologic deficiency of endogenous cysteine synthesis in infancy. This is why the disease is age-restricted and why exogenous cysteine/NAC supplementation is disease-modifying rather than merely supportive.

3. Phenotypes

Frequencies below are from the largest published cohort of 60 untreated symptomatic children (GeneReviews/Vogel et al. 2023):

Phenotype Characteristics

• Onset: classically 2–4 months of age; presymptomatic/prenatally treated at-risk siblings can be identified and managed before symptom onset.
• Course: episodic/acute and — in survivors — self-limited and reversible, distinguishing this from most other mitochondrial hepatopathies (e.g., DGUOK, MPV17, POLG-related disease), which are progressive. Genetics in Medicine cohort work also documents a broader phenotypic spectrum, including patients without overt liver failure, some presenting instead with Leigh-syndrome-like neuroimaging (symmetric restricted diffusion in thalami/putamen), chronic respiratory failure, or isolated myopathy (Murali et al. 2021, PMID: 33485800).
• Severity/variability: highly variable — from fatal neonatal multiorgan failure to mild, self-resolving transaminitis; genotype (LOF vs. missense) and treatment timing are major severity modifiers.
• Hepatic copper accumulation has been reported as a possible secondary, cholestasis-associated feature in at least one case (Grover et al., JIMD Reports, PMID: 25665837), postulated to be secondary to cholangiopathy rather than a primary TRMU effect.
• Quality of life: for survivors, long-term outcomes are generally favorable; among 25 followed individuals in the GeneReviews cohort, 9 had full resolution of developmental delay following liver recovery, while 5 had persistent developmental delays — indicating QOL impact is concentrated in the acute period and in the minority with residual neurodevelopmental sequelae.

4. Genetic/Molecular Information

Causal Gene

• TRMU (HGNC:25481; OMIM *610230), chromosome 22q13.31. Encodes tRNA 5-methylaminomethyl-2-thiouridylate methyltransferase (also known as mitochondrial tRNA-specific 2-thiouridylase 1, MTU1).

Gene Function

TRMU is a nuclear-encoded, mitochondrially targeted enzyme that catalyzes 2-thiolation of uridine at the wobble (position 34) anticodon position of three mitochondrial tRNAs — mt-tRNA^Lys, mt-tRNA^Glu, and mt-tRNA^Gln — generating the modified nucleoside 5-taurinomethyl-2-thiouridine (τm5s2U). This modification is essential for accurate codon-anticodon pairing, translational fidelity, and structural stability of these tRNAs (PubMed 16513084; Suzuki lab reviews, WIREs RNA 2011).

Pathogenic Variants

• Variant types: missense (most common), nonsense, frameshift, splice-site, small indels, and gene-level deletion/duplication (rare).
• ACMG classification: cataloged in ClinVar (e.g., RCV001277295, RCV000351468) predominantly as Pathogenic/Likely Pathogenic when biallelic and segregating with disease.
• Allele frequency: specific gnomAD population allele-frequency figures were not identified in available secondary sources beyond the qualitative statement that overall disease prevalence is <1 per 1,000,000 (OMIM) with founder-elevated frequency of c.229T>C (p.Tyr77His) in the Yemenite Jewish population.
• Somatic vs. germline: exclusively germline (biallelic recessive); no somatic TRMU disease association reported.
• Functional consequence: loss of function — reduced or absent thiolation activity leads to loss of τm5s2U modification, reduced steady-state levels of the three target mt-tRNAs, impaired mitochondrial translation of OXPHOS subunits, and downstream respiratory chain complex I, III, and IV deficiency (GeneReviews; muscle biopsy shows decreased complex I/III/IV activity and ragged red fibers).
• A 2024 mechanistic paper (Nucleic Acids Research, doi:10.1093/nar/gkad1197) shows that pathological MTU1 mutations promote proteolysis of the MTU1 protein via mitochondrial caseinolytic peptidase (CLPP), providing a protein-stability mechanism for how missense variants cause loss of function.

Modifier Genes

• TRMU acts as a nuclear modifier gene for the phenotypic expression of the deafness-associated mitochondrial 12S rRNA m.1555A>G mutation — i.e., TRMU variants can modulate penetrance/severity of aminoglycoside-induced and non-syndromic hearing loss in carriers of 12S rRNA mutations (Guan et al., PMID: 16513084). This is a related but mechanistically and clinically distinct TRMU-associated phenotype (maternally inherited deafness) from the infantile liver failure syndrome, and should not be conflated with it.
• Related paralogous tRNA-thiolation pathway genes GTPBP3 and MTO1 cause overlapping/similar τm5s2U-modification-deficiency phenotypes (deafness, reversible liver failure, hypertrophic cardiomyopathy, lactic acidosis) and are relevant differential-diagnosis/pathway partners.

Epigenetic Information

A study describes microRNA-mediated differential expression of TRMU, GTPBP3, and MTO1 in cell models of mitochondrial-DNA disease (PMC5524753), suggesting post-transcriptional/epigenetic-adjacent regulation of this pathway, though this is not established as a primary disease mechanism in TRMU deficiency itself.

Chromosomal Abnormalities

No large-scale chromosomal rearrangements (aneuploidy, translocation) are reported as a cause; disease is driven by intragenic sequence-level variants.

5. Environmental Information

• No toxic/occupational/pollutant etiology is established; this is a monogenic mitochondrial disease.
• Nutritional/metabolic environment: the infant's transient physiologic cysteine deficiency (low cystathionase activity) functions as the key "environmental" (developmental-metabolic) permissive factor.
• Infectious triggers: intercurrent viral illness (e.g., CMV, reported in one fatal case) can precipitate or worsen acute decompensation, acting as a physiologic stressor rather than a primary cause.
• Drugs to avoid (iatrogenic environmental risk factors that worsen mitochondrial function or increase metabolic demand): corticosteroids, valproic acid, prolonged propofol infusion, fasting, and acetaminophen during liver dysfunction — all flagged in GeneReviews management guidance as agents that can exacerbate hepatic/mitochondrial decompensation.

6. Mechanism / Pathophysiology

Causal Chain

1. Molecular trigger: Biallelic TRMU loss-of-function variants → loss of 2-thiouridylase activity on mt-tRNA^Lys, mt-tRNA^Glu, mt-tRNA^Gln (loss of τm5s2U wobble modification).
2. RNA-level consequence: Reduced steady-state levels/stability of thio-modified mitochondrial tRNAs; impaired aminoacylation and codon-anticodon decoding fidelity.
3. Translational consequence: Impaired mitochondrial protein synthesis — specifically of the 13 mtDNA-encoded OXPHOS subunits — causing combined respiratory chain deficiency (complexes I, III, IV, all of which contain mtDNA-encoded subunits reliant on these tRNAs).
4. Cellular consequence — proteostress/UPR activation: A key mechanistic paper (Cell Reports, PMID: 29320742) shows that defective mt-tRNA taurine modification (via Mto1/Trmu loss) causes mistrafficking and cytoplasmic aggregation/misfolding of nuclear-DNA-encoded mitochondrial proteins (e.g., OPA1), which activates a cytotoxic unfolded protein response (UPR) and global proteostasis stress — a mechanism distinct from, and additive to, simple OXPHOS insufficiency.
5. Tissue/organ consequence: Hepatocyte energy failure, cell death (apoptosis/necrosis), and macrophage infiltration. A liver-specific conditional Mtu1 knockout mouse model shows hepatocellular injury with karyomegaly/multinucleation, macrophage infiltration, and spotty necrosis, without fibrosis — closely recapitulating human RILF histology (PLOS Genetics, PMID: 27689697; follow-up NAR work).
6. Clinical manifestation: Acute hepatic decompensation (jaundice, coagulopathy, transaminitis), systemic lactic acidosis (impaired oxidative phosphorylation → compensatory anaerobic glycolysis), hypoglycemia, and (in a subset) CNS involvement resembling Leigh syndrome (thalamic/putaminal restricted diffusion) and cardiomyopathy.
7. Reversibility mechanism: Because the defect is a modifiable post-transcriptional RNA modification rather than a structural/genomic lesion, and because the developmental cysteine deficiency is time-limited, hepatocyte and mitochondrial function can recover once the infant ages past the vulnerable cysteine-deficient window and/or receives exogenous sulfur-donor supplementation — explaining the "transient" clinical hallmark unique among mitochondrial hepatopathies.

Molecular Pathways

• Mitochondrial tRNA wobble-position modification pathway (τm5s2U biosynthesis: TRMU, GTPBP3, MTO1 cooperate).
• Mitochondrial translation machinery (mitoribosome-dependent synthesis of OXPHOS subunits).
• Oxidative phosphorylation / electron transport chain (Complexes I, III, IV).
• Unfolded protein response (mitochondrial and cytosolic UPR) triggered by protein mistargeting.

Cellular Processes

Apoptosis/necrosis of hepatocytes; mitochondrial biogenesis impairment; proteostasis/UPR activation; inflammatory macrophage recruitment; (in bone-related studies) impaired osteogenic differentiation has also been linked to Mtu1 defects (Cell Death & Disease, PMC on osteogenic differentiation), suggesting a broader cell-differentiation impact of τm5s2U loss beyond hepatocytes.

Protein Dysfunction

Loss-of-function/reduced enzymatic activity of TRMU protein; some pathogenic missense variants additionally destabilize the protein and target it for proteolysis via mitochondrial CLPP protease, compounding the enzymatic defect with reduced protein abundance (NAR 2024, doi:10.1093/nar/gkad1197).

Metabolic Changes

Lactic acidosis (impaired pyruvate oxidation via ETC dysfunction); hypoglycemia (impaired hepatic gluconeogenesis/energy failure); hyperammonemia (impaired urea cycle function secondary to hepatocellular failure); disrupted sulfur amino acid (cysteine/taurine) metabolism as the central biochemical lever of both pathogenesis and treatment.

Immune System Involvement

Secondary innate immune activation — macrophage infiltration into injured liver tissue is a consistent histologic finding in both human liver biopsies and the mouse model, reflecting a response to hepatocyte injury rather than primary autoimmune/immunodeficiency pathology.

Tissue Damage Mechanisms

Hepatocellular necrosis/apoptosis, oxidative-phosphorylation failure-driven energy crisis, and proteostress-induced cytotoxicity converge on hepatocyte death; histologically the human liver shows bridging fibrosis, cirrhosis (in some cases), steatosis, and mitochondrial proliferation on biopsy (GeneReviews).

Biochemical Abnormalities

Specific enzymatic defect: loss of mitochondrial tRNA 2-thiouridylase activity (EC 2.8.1.-); combined respiratory chain complex I, III, IV deficiency on muscle biopsy enzymology.

Suggested Ontology Terms

• GO (Biological Process): GO:0002143 (tRNA wobble position uridine thiolation), GO:0032543 (mitochondrial translation), GO:0006120 (mitochondrial electron transport, NADH to ubiquinone), GO:0034341 (response to type II interferon — not core), GO:0006986 (response to unfolded protein / UPR-related terms), GO:0006915 (apoptotic process).
• GO (Cellular Component): GO:0005739 (mitochondrion), GO:0005759 (mitochondrial matrix), GO:0005743 (mitochondrial inner membrane).
• CL (Cell Type): CL:0000182 (hepatocyte), CL:0000235 (macrophage), CL:0000187 (muscle cell — for the myopathic phenotype).

7. Anatomical Structures Affected

Organ Level

• Primary organ: Liver (UBERON:0002107) — the dominant and most consistent manifestation.
• Secondary/associated organ involvement: brain (Leigh-syndrome-like lesions in thalami, putamen, basal nuclei, pontine tracts — UBERON:0001897 thalamus, UBERON:0001874 putamen), heart (cardiomyopathy — UBERON:0000948), skeletal muscle (myopathy, ragged red fibers — UBERON:0001134), inner ear (sensorineural hearing loss, in the broader spectrum/related deafness phenotype — UBERON:0001846 cochlea).
• Body systems: hepatic, metabolic/endocrine (hypoglycemia, lactic acidosis), hematologic (coagulopathy), neurologic, cardiovascular, and (in related phenotypes) audiologic.

Tissue and Cell Level

• Hepatocytes (CL:0000182) — primary target of injury.
• Kupffer cells/macrophages (CL:0000235) — secondary inflammatory infiltration.
• Skeletal muscle fibers with ragged red fiber morphology (mitochondrial proliferation).
• Cochlear hair cells (in zebrafish model and in human deafness-associated phenotype).

Subcellular Level

• Mitochondrial matrix (GO:0005759) — site of tRNA modification defect and impaired translation.
• Mitochondrial inner membrane (GO:0005743) — site of the respiratory chain complexes affected.
• Cytoplasm — secondary site of misfolded/mistargeted protein aggregation (proteostress mechanism).

Localization

Diffuse/bilateral, symmetric involvement is typical for the brain lesions (symmetric thalamic/putaminal restricted diffusion) — not lateralized. Liver involvement is diffuse (whole-organ hepatocellular dysfunction), not focal.

8. Temporal Development

• Onset: typically 2–4 months of age (infantile), occasionally as early as neonatal or as late as ~1 year; presymptomatic identification possible in at-risk siblings via prenatal/newborn testing.
• Onset pattern: acute — episodes of decompensation are abrupt, often precipitated by intercurrent illness.
• Disease course pattern: episodic and, in survivors, self-limited/monophasic — this is the disease's defining feature. Acute liver failure occurs only in the first year of life (43/62 in the largest cohort); survivors of the initial episode show clinical/biochemical resolution and no further episodes (OMIM #613070).
• Progression rate: rapid during the acute episode (can progress to multiorgan failure and death within weeks); but the overall disease is not chronically progressive in survivors, unlike most mitochondrial hepatopathies.
• Critical period: the first ~4–6 months of life, corresponding to the developmental nadir of endogenous cystathionase activity — the key window for both risk and for the protective effect of early cysteine/NAC supplementation.
• Remission: spontaneous biochemical/clinical resolution occurs in survivors after the acute window passes, and is further improved by treatment (cysteine supplementation); this is not "treatment-induced remission" in the oncologic sense but genuine reversal of the acute hepatopathy.

9. Inheritance and Population

Epidemiology

• Prevalence: <1 per 1,000,000 (OMIM), consistent with an ultra-rare disease.
• Cohort size reported to date: 62 individuals from 56 families in the largest combined cohort (GeneReviews/Vogel et al. 2023, Genet Med, PMID: 36305855).

Inheritance Pattern

• Autosomal recessive. For carrier parents: 25% risk of an affected child, 50% risk of a carrier child, 25% risk of an unaffected/non-carrier child per pregnancy (GeneReviews).

Penetrance / Expressivity

• Penetrance and expressivity are variable — presentation ranges from asymptomatic/mild transaminitis to fatal multiorgan failure, with genotype (LOF vs. missense) as a major modifier of severity.

Founder Effects

• c.229T>C (p.Tyr77His) is a well-established founder variant in the Yemenite Jewish population, first reported by Zeharia et al. (2009, PMID: 19732863).

Consanguinity

• As an autosomal recessive disease, consanguineous unions increase risk in affected families/populations, consistent with the founder-population pattern described.

Population Demographics

• Highest documented ancestry association: Yemenite Jewish founder population; cases are otherwise reported across diverse ethnicities/geographies (cohorts include patients from the US, China, and elsewhere), indicating global but very low-frequency distribution with no single dominant geographic endemic focus outside the noted founder population.
• Sex ratio: no sex predilection reported (autosomal recessive; no data suggesting skew).
• Age distribution of affected individuals: concentrated in the first year of life at symptom onset; median age at death (in fatal cases) reported as ~3 months.

10. Diagnostics

Clinical/Laboratory Tests

• Liver function panel: elevated transaminases (AST/ALT), elevated bilirubin, coagulopathy (elevated INR/PT).
• Metabolic panel: elevated serum/plasma lactate (HP:0002151), hypoglycemia, hyperammonemia.
• Muscle biopsy: ragged red fibers; decreased respiratory chain complex I, III, IV enzyme activities.
• Liver biopsy histology: bridging fibrosis, cirrhosis, steatosis, mitochondrial proliferation.
• Brain MRI: variable lesions in thalami, putamen, basal ganglia, and pontine tracts (Leigh-syndrome-like), which may normalize after clinical recovery.

Genetic Testing

• Diagnosis is established by molecular genetic testing identifying biallelic pathogenic TRMU variants.
• Approach: mitochondrial disease, cholestasis, or acute infantile liver failure multigene panels; or comprehensive genomic testing (exome/genome sequencing) when the phenotype is broad/atypical.
• Yield: sequence analysis detects ~93% of pathogenic alleles (26/28); deletion/duplication analysis detects the remainder (~7%, 2/28) (GeneReviews Table 2).
• Prenatal/presymptomatic testing: feasible and clinically used in at-risk families with a known familial variant, enabling presymptomatic/prenatal cysteine supplementation (as documented in multiple case reports).

Differential Diagnosis (from GeneReviews)

Deoxyguanosine kinase (DGUOK) deficiency; Leigh syndrome (>90 causal genes); POLG-related Alpers-Huttenlocher syndrome; SERAC1 deficiency; other mtDNA maintenance disorders (MPV17, DGUOK); organic acidemias (propionic acidemia, methylmalonic acidemia); fatty acid oxidation disorders (MCAD, VLCAD, SCAD deficiency); glycogen storage disease type Ia. Related genes in the same τm5s2U-modification pathway — GTPBP3 and MTO1 — cause phenotypically overlapping disease (deafness, reversible liver failure, hypertrophic cardiomyopathy, lactic acidosis) and should specifically be considered/excluded.

Screening

No population-based newborn screening currently exists for TRMU deficiency specifically (it is not part of standard NBS panels); the recommended approach in suspected/at-risk cases is targeted familial variant testing and prenatal diagnosis once a proband is identified, combined with a low-risk empiric-treatment strategy (starting cysteine/NAC supplementation) in symptomatic infants with compatible biochemistry (persistent lactic acidosis + hypoglycemia) even before molecular confirmation, given its safety and time-critical benefit (Murali et al. 2021, PMID: 33485800).

11. Outcome/Prognosis

Survival and Mortality

• Mortality among symptomatic children: 20/60 (33%) died in the largest reported cohort.
• Causes: 8 from liver failure complications, 8 from multiorgan failure, 3 from cardiorespiratory failure, 1 from sepsis.
• Median age at death: 3 months.
• Overall cohort survival (all 62 individuals, symptomatic and presymptomatic combined): 42/62 alive at a median age of 6.8 years, median follow-up 3.6 years (Vogel et al. 2023 per WebSearch synthesis of GeneReviews/GIM data).
• Impact of cysteine/NAC supplementation on survival: survival beyond acute decompensation was 84% in supplemented children vs. 61% in unsupplemented children (GeneReviews, citing Vogel et al. 2023) — a substantial, clinically actionable treatment effect.
• Genotype effect on survival: LOF variants → 10/20 deaths; missense/in-frame indel variants → 10/42 deaths (p=0.022). The Yemenite founder variant p.Tyr77His is associated with the lowest mortality (0/8 homozygotes, 1/9 compound heterozygotes died).
• Follow-up duration by variant class: nonsense/frameshift/splice variant carriers had shorter average follow-up (38 months) than missense/in-frame indel carriers (78 months), consistent with earlier mortality in the LOF group.

Morbidity / Functional Outcomes

• Among 25 long-term followed individuals: 9 had full resolution of neurodevelopmental delay after liver recovery; 5 had persistent developmental delays.
• Liver transplantation does not appear to improve overall survival: 11 children underwent orthotopic liver transplantation at a median age of 4 months, but two post-transplant deaths were reported, and GeneReviews states transplantation "did not influence overall survival" — an important finding given that this is otherwise a self-limited disease, meaning transplant may treat a transient problem with a permanent, high-risk intervention.

Prognostic Factors

• Genotype (LOF vs. missense), timing of cysteine/NAC initiation (pre-symptomatic/early vs. late), and severity of the initial acute episode are the principal prognostic determinants identified to date.

12. Treatment

Targeted (Disease-Modifying) Therapy: Sulfur-Donor Supplementation

This is the only disease-specific/targeted therapy currently established, and represents a genuine precision-metabolic intervention aimed directly at the enzymatic substrate deficiency.

• Regimen: combined L-cysteine (85–300 mg/kg/day, goal 300 mg/kg/day) and N-acetylcysteine (NAC) (70–150 mg/kg/day; proposed total combined goal 300 mg/kg/day with 150 mg/kg/day as NAC) (GeneReviews; Murali et al. 2021, PMID: 33485800).
• Duration: minimum through the first year of life (the vulnerable cysteine-deficient developmental window).
• Mechanism: provides exogenous sulfur donor to compensate for reduced TRMU enzymatic capacity and for the physiologic infantile cystathionase nadir, increasing thiouridylation of residual/partially functional mitochondrial tRNAs.
• Evidence: multiple case reports (e.g., Sasarman et al., ScienceDirect S2214426918301332 — "L-Cysteine supplementation prevents liver transplantation in a patient with TRMU deficiency") and cohort data (84% vs. 61% survival, above) support benefit; presymptomatic/prenatal initiation produces the mildest courses.
• NCIT term suggestion: NCIT:C15986 (Pharmacotherapy) as the treatment action, with therapeutic_agent bound to CHEBI for L-cysteine (CHEBI:17561) and N-acetylcysteine (CHEBI:47704).

Supportive Care

• Management of hypoglycemia, lactic acidosis, coagulopathy, and hyperammonemia during acute episodes.
• Feeding support (may require gastrostomy tube) for failure to thrive.
• Seizure management as needed.
• Cardiac monitoring (given cardiomyopathy risk).
• Developmental/early intervention services (ages 0–3) and special education as needed for children with persistent neurodevelopmental delay.
• NCIT terms: NCIT:C15747 (Supportive Care), NCIT:C15302 (Physical Therapy)/rehabilitation as applicable.

Surgical/Interventional

• Orthotopic liver transplantation: has been performed (11 children at median age 4 months in the largest cohort) for hepatopathy unresponsive to medical management, but does not appear to improve overall survival compared with medical management given the disease's transient/reversible natural history — a critical nuance for clinical decision-making (avoid unless truly refractory, given the risk of transplanting a self-limited disease). NCIT:C15289 (Organ Transplantation).

Agents to Avoid (iatrogenic risk)

• Corticosteroids (increase metabolic demand).
• Valproic acid and prolonged propofol infusion (mitochondrial toxicity/inhibition).
• Fasting (worsens hypoglycemia and metabolic demand).
• Acetaminophen during active liver dysfunction.

Experimental/Research Directions

No gene therapy, RNA-based therapy, or targeted molecular therapy beyond sulfur-donor supplementation is currently in clinical trials specifically for TRMU deficiency, per available search results; mechanistic work on CLPP-mediated proteolysis of mutant MTU1 protein (NAR 2024) suggests a potential future therapeutic angle (e.g., CLPP inhibition to stabilize residual mutant protein), but this remains preclinical.

Treatment Strategy / Algorithm

Given the low risk and potential high benefit, GeneReviews and Murali et al. recommend empiric initiation of combined L-cysteine + NAC supplementation in any infant with persistent lactic acidosis and hypoglycemia suggestive of TRMU deficiency, even prior to molecular confirmation, alongside standard supportive metabolic/hepatic care, while genetic testing is pending.

13. Prevention

Primary Prevention

No population-level primary prevention (e.g., vaccination) applies to this genetic disease. The principal actionable "prevention" is presymptomatic identification and early/prenatal cysteine-NAC supplementation in at-risk siblings once a family's causal variant is known — documented to blunt disease severity substantially.

Screening and Early Detection

• Genetic carrier screening / cascade testing: recommended in families with a known affected child, especially relevant in populations with elevated carrier frequency (e.g., Yemenite Jewish ancestry) — following the standard ACMG/genetic-counseling framework for autosomal recessive disease.
• Prenatal diagnosis: has been used clinically (e.g., a documented case of prenatal L-cysteine initiation in the third trimester based on prenatal molecular diagnosis).
• Not currently part of routine population newborn screening panels.

Genetic Counseling

Standard autosomal recessive counseling: 25%/50%/25% recurrence risk pattern per pregnancy for carrier couples; particular relevance for genetic counseling in Yemenite Jewish families given the founder variant.

Prophylaxis

Early/prophylactic cysteine + NAC supplementation in genetically identified at-risk (presymptomatic) infants functions as a form of secondary/tertiary prevention, reducing severity of the first (and typically only) disease episode.

14. Other Species / Natural Disease

• No naturally occurring TRMU-deficiency disease has been reported in companion animals or wildlife in the literature surveyed; this appears to be a laboratory-model-only cross-species picture (see Model Organisms, below) rather than a naturally occurring veterinary disease.
• Orthologous gene: Trmu/Mtu1 is conserved across vertebrates (mouse Trmu, NCBI Gene; zebrafish trmu/mtu1, ZFIN ZDB-GENE-050522-540), reflecting deep evolutionary conservation of the mitochondrial tRNA thiolation pathway.

15. Model Organisms

Zebrafish (Danio rerio)

• mtu1 (trmu) knockout zebrafish (Zhou et al., Nucleic Acids Research 2018, PMID: 30137487; full text) show:
• Abolished 2-thiouridine modification of mt-tRNA^Lys, mt-tRNA^Glu, mt-tRNA^Gln.
• Impaired mitochondrial translation, respiratory complex activity reduced to 38–83% of wild-type, mitochondrial ATP production reduced to ~51% in homozygous mutants.
• Auditory/vestibular phenotype: abnormal startle response and swimming behavior (~42% of larvae abnormal swimming, ~23% weak/absent startle), reduced saccular otolith size, reduced hair cell numbers and hair bundle density in inner ear structures — modeling the deafness component of the human TRMU-associated phenotypic spectrum, though this particular model did not recapitulate liver pathology at the stages examined.
• A related zebrafish model of Mto1 ablation (pathway partner gene) shows hypertrophic cardiomyopathy via mitochondrial RNA maturation deficiency (PMC8096277), relevant as a comparative model for the cardiomyopathy phenotype seen in a subset of human TRMU-deficiency patients.

Mouse (Mus musculus)

• Global Mtu1 (Trmu) knockout is embryonic lethal at a very early developmental stage, precluding study of postnatal disease in constitutive knockouts.
• Liver-specific conditional knockout mice (Mtu1-LKO) show:
• Severe liver injury with hepatocyte cell death, macrophage infiltration, and spotty necrosis.
• Enlarged hepatocytes with karyomegaly and multinucleation.
• Notably, no significant fibrosis, distinguishing the acute-injury mouse model from some human biopsy findings of fibrosis/cirrhosis in severe cases.
• This model is described as closely resembling the histologic features of human RILF (PLOS Genetics, PMID: 27689697, "Mtu1-Mediated Thiouridine Formation of Mitochondrial tRNAs Is Required for Mitochondrial Translation and Is Involved in Reversible Infantile Liver Injury").
• Additional mouse/cell-based work links Mtu1 defects to impaired osteogenic differentiation (Cell Death & Disease, doi:10.1038/s41419-020-03345-5), suggesting a broader tissue impact of the pathway beyond liver, ear, and heart that may be under-recognized clinically.

Model Recapitulation Assessment

• Zebrafish model: high fidelity for the auditory/hair-cell and mitochondrial bioenergetic phenotype; does not recapitulate the hepatic phenotype at examined stages — a translational gap (candidate for a HUMAN_MODEL_MISMATCH-type annotation if curated into a knowledge base).
• Liver-conditional mouse model: high fidelity for acute hepatocellular injury/macrophage infiltration; partially recapitulates human histology (misses fibrosis seen in some human cases) and, being an induced conditional knockout, does not model the transient/reversible natural history directly (the mouse model is not reported to spontaneously resolve).
• Global mouse knockout: fails to recapitulate any postnatal phenotype due to embryonic lethality, underscoring that a full-body, physiological TRMU-null state is likely incompatible with life in mammals — a key mechanistic insight, since human patients rarely if ever carry complete null/null genotypes (most surviving patients carry at least one hypomorphic/missense allele).

Summary of Key Evidence-Grade Citations

Notes on Information Gaps

• Specific gnomAD population allele-frequency and carrier-frequency figures for individual TRMU pathogenic variants were not retrievable from the sources searched (beyond the qualitative OMIM prevalence estimate of <1/1,000,000 and the known Yemenite Jewish founder-variant enrichment); direct gnomAD/ClinVar query would be needed to populate this precisely.
• Detailed transcriptomic/proteomic/metabolomic dataset accessions (GEO, MetaboLights, etc.) specific to TRMU-deficiency patient or model-organism samples were not identified in this search and may require a dedicated dataset-repository search (e.g., GEO query for "TRMU" or "Mtu1").
• Full OMIM Clinical Synopsis (categorized organ-system checklist) and the complete Genetics in Medicine full-text (both paywalled/403 in this session) could supplement further granular phenotype-frequency and variant-table detail if full-text access is available in a curation environment (e.g., via institutional subscription or PubMed Central when eligible).

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0009723 (1 mention) - the report calls it "MONDO"; MONDO calls it Leigh syndrome
• CL:0000187 (1 mention) - the report calls it "muscle cell — for the myopathic phenotype"; CL calls it muscle cell
• UBERON:0002107 (1 mention) - the report calls it "Liver", "Primary organ: Liver"; UBERON calls it liver

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0001928 (1 mention) - the report calls it "Abnormal coagulation"; HP calls it Abnormality of coagulation
• GO:0034341 (1 mention) - the report calls it "response to type II interferon — not core"; GO calls it response to type II interferon
• GO:0006986 (1 mention) - the report calls it "response to unfolded protein / UPR-related terms"; GO calls it response to unfolded protein
• CL:0000235 (2 mentions) - the report calls it "macrophage", "Kupffer cells/macrophages"; CL calls it macrophage
• HP:0002151 (1 mention) - the report calls it "Metabolic panel: elevated serum/plasma lactate"; HP calls it Increased circulating lactate concentration**, and lists "Increased serum lactate" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• GO:0005759 - called "mitochondrial matrix", "Mitochondrial matrix"
• GO:0005743 - called "mitochondrial inner membrane", "Mitochondrial inner membrane"
• CL:0000182 - called "hepatocyte", "Hepatocytes"
• CL:0000235 - called "macrophage", "Kupffer cells/macrophages"
• UBERON:0002107 - called "Liver", "Primary organ: Liver"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.